The Itch You Cannot Scratch: Veterinary Dermatology
Science and Compliance
QCS Session #9 - Panel Discussion
QCS Session #8 - Sterility Assurance using Sterile Compounding Automation and Technology
QCS Session #7 - API or Approved Product: Where do we start with veterinary compounds?
QCS Session #6 - Cleanroom Certification - Digging Deeper
QCS Session #5 - Root Cause of Stability Failures
QCS Session #4 - Regulatory and Quality Considerations in the Selection of API
QCS Session #3 - Quality Compounding and Clinical Pharmaceutics
QCS Session #2 - Pharmacist/Provider/Patient Triad: A Multidisciplinary Approach to Patient Care
QCS Session #1 -NABP Implementation of the FDA Compounding MOU
Raw Material Revealed
A Pharmacist’s Prescription for Bringing in New Customers
Insurance Considerations for Pharmacists and Professional Liability in Compounding
COVID-19 Testing and Therapeutics
Minor Chapters Major Impacts: What USP 51, 61 and 1207 Mean for Your Practice
More than Selling Compounds
Rapid Sterility Testing Strategies for Compounded Sterile Preparations
Stability Testing: Science and Compliance
Discover New Business Opportunities for Your Pharmacy
Rapid Sterility Testing
USP 800 Update – What is the current status and how do pharmacists proceed?
Beyond Use Date Strategies for Compounded Sterile Preparations
USP General Chapters and Compounded Monograph Chapters: Best Practices and Regulatory Guidance
Medical Marijuana (THC and CBD) Pharmacology, Regulation, and Pharmacy Considerations
The Practical Use of the USP as a Primary Reference Resource in Compounded Formulations
Stability Studies: The Architecture Behind Establishing a Beyond-Use-Date
Compounded Sterile Products: Extending Beyond Use Dating and Batch Release Testing for 503A and 503B Facilities
An Inside Look at USP <71>
USP <800> and Environmental Monitoring Requirements
Stability Indicating Methods
Extending Beyond Use Dating for Compounding Preparations
Microbiology Testing: USP Requirements for Sterile and Non-Sterile Preparations